Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02013180|
Recruitment Status : Completed
First Posted : December 17, 2013
Results First Posted : April 15, 2019
Last Update Posted : April 15, 2019
Although Prostate Specific Antigen (PSA) is a useful marker for early detection of the prostate cancer, its specivity is not sufficient. Several PSA variations were defined in order to increase the specivity of the test, but they aren't much more effective than the PSA alone for detection of disease.
In older studies reported that, serum and prostatic tissue zinc levels decreased in prostat cancer disease.
In our study we aimed to establish the utility of serum zinc, PSA, free PSA/PSA (fPSA/tPSA), zinc/PSA, levels for early detection of the prostate cancer.
|Condition or disease|
|Prostate Cancer Detection|
|Study Type :||Observational|
|Actual Enrollment :||480 participants|
|Official Title:||Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection|
|Study Start Date :||July 2012|
|Actual Primary Completion Date :||January 2013|
|Actual Study Completion Date :||January 2017|
prostate adenocarcinoma in pathologic evaluation
benign prostatic diseases in pathologic evaluation
- Assesment of Serum Zinc/PSA Ratio in Patients With Prostate Cancer and Benign Prostatic Diseases [ Time Frame: measurement of serum zinc and PSA levels are performed prior to transrectal prostat biopsy; pathologic evaluation of biopsy specimens are performed within 2-3 weeks ]Does the zinc/PSA ratio show statistically signifacant difference in patients with prostate cancer?
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02013180
|Bagcilar Training and Research Hospital-Depertmant of Urology|
|Istanbul, Bagcilar, Turkey, 34100|